Topic
Profile of mood states
About: Profile of mood states is a research topic. Over the lifetime, 2008 publications have been published within this topic receiving 107283 citations.
Papers published on a yearly basis
Papers
More filters
TL;DR: Gabapentin monotherapy appears to be efficacious for the treatment of pain and sleep interference associated with diabetic peripheral neuropathy and exhibits positive effects on mood and quality of life.
Abstract: Context.—Pain is the most disturbing symptom of
diabetic peripheral neuropathy. As many as 45% of patients with
diabetes mellitus develop peripheral neuropathies.Objective.—To evaluate the effect of gabapentin monotherapy
on pain associated with diabetic peripheral neuropathy.Design.—Randomized, double-blind, placebo-controlled,
8-week trial conducted between July 1996 and March 1997.Setting.—Outpatient clinics at 20 sites.Patients.—The 165 patients enrolled had a 1- to 5-year
history of pain attributed to diabetic neuropathy and a minimum 40-mm
pain score on the Short-Form McGill Pain Questionnaire visual analogue
scale.Intervention.—Gabapentin (titrated from 900 to 3600
mg/d or maximum tolerated dosage) or placebo.Main Outcome Measures.—The primary efficacy measure was
daily pain severity as measured on an 11-point Likert scale (0, no
pain; 10, worst possible pain). Secondary measures included sleep
interference scores, the Short-Form McGill Pain Questionnaire scores,
Patient Global Impression of Change and Clinical Global Impression of
Change, the Short Form–36 Quality of Life Questionnaire scores, and
the Profile of Mood States results.Results.—Eighty-four patients received gabapentin and 70
(83%) completed the study; 81 received placebo and 65 (80%) completed
the study. By intent-to-treat analysis, gabapentin-treated patients'
mean daily pain score at the study end point (baseline, 6.4; end point,
3.9; n = 82) was significantly lower (P<.001) compared with
the placebo-treated patients' end-point score (baseline, 6.5; end
point, 5.1; n = 80). All secondary outcome measures of pain were
significantly better in the gabapentin group than in the placebo group.
Additional statistically significant differences favoring gabapentin
treatment were observed in measures of quality of life (Short Form–36
Quality of Life Questionnaire and Profile of Mood States). Adverse
events experienced significantly more frequently in the gabapentin
group were dizziness (20 [24%] in the gabapentin group vs 4
[4.9%] in the control group; P<.001) and somnolence (19
[23%] in the gabapentin group vs 5 [6%] in the control group;
P = .003). Confusion was also more frequent in the gabapentin
group (7 [8%] vs 1 [1.2%]; P = .06).Conclusion.—Gabapentin monotherapy appears to be
efficacious for the treatment of pain and sleep interference associated
with diabetic peripheral neuropathy and exhibits positive effects on
mood and quality of life.
1,442 citations
TL;DR: The feasibility of using a shorter version of the Profile of Mood States is examined, indicating the suitability of the short version for estimating the original mood scale scores in this population of cancer patients.
Abstract: The feasibility of using a shorter version of the Profile of Mood States is examined. Eighty-three cancer patients were administered the Profile of Mood States. The scales' internal consistency (coefficient alpha) and the items' face validity were used as criteria for eliminating items. The number of items was reduced from 65 to 37 and the correlation coefficients between the short and original scales were all above .95, indicating the suitability of the short version for estimating the original mood scale scores in this population.
1,165 citations
TL;DR: A mindfulness meditation–based stress reduction program was effective in decreasing mood disturbance and stress symptoms in both male and female patients with a wide variety of cancer diagnoses, stages of illness, and ages.
Abstract: Objective: The objective of this study was to assess the effects of participation in a mindfulness meditation‐ based stress reduction program on mood disturbance and symptoms of stress in cancer outpatients. Methods: A randomized, wait-list controlled design was used. A convenience sample of eligible cancer patients enrolled after giving informed consent and were randomly assigned to either an immediate treatment condition or a wait-list control condition. Patients completed the Profile of Mood States and the Symptoms of Stress Inventory both before and after the intervention. The intervention consisted of a weekly meditation group lasting 1.5 hours for 7 weeks plus home meditation practice. Results: Ninety patients (mean age, 51 years) completed the study. The group was heterogeneous in type and stage of cancer. Patients’ mean preintervention scores on dependent measures were equivalent between groups. After the intervention, patients in the treatment group had significantly lower scores on Total Mood Disturbance and subscales of Depression, Anxiety, Anger, and Confusion and more Vigor than control subjects. The treatment group also had fewer overall Symptoms of Stress; fewer Cardiopulmonary and Gastrointestinal symptoms; less Emotional Irritability, Depression, and Cognitive Disorganization; and fewer Habitual Patterns of stress. Overall reduction in Total Mood Disturbance was 65%, with a 31% reduction in Symptoms of Stress. Conclusions: This program was effective in decreasing mood disturbance and stress symptoms in both male and female patients with a wide variety of cancer diagnoses, stages of illness, and ages. Key words: meditation, cancer, stress, mood, intervention, mindfulness. ANOVA 5 analysis of variance; MANOVA 5 multiple analysis of variance; POMS 5 Profile of Mood States; SOSI 5 Symptoms of Stress Inventory.
1,086 citations